Special Issue "Peptide-Based and Hybrid Carriers for Nucleic Acids Delivery"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 895

Special Issue Editors

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint-Petersburg, Russia
Interests: gene therapy; nucleic acids delivery; gene silencing; gene expression; peptide-based carriers; receptor-mediated delivery; transfection; genetic testing; spinal muscular atrophy; uterine leiomyoma; endometriosis; duchenne muscular dystrophy; cellular models; animal models
1. Institute of Macromolecular Compounds, Russian Academy of Sciences, 199004 St. Petersburg, Russia
2. Institute of Chemistry, Saint-Petersburg State University, 199034 St. Petersburg, Russia
Interests: bio-inspired polymers; biodegradable polymers; biopolymers; ring-opening polymerization; free radical polymerization; controlled radical polymerization; copolymers; amphiphilic copolymers; self-assembly; polymer nanoparticles; macroporous polymer materials; biocomposites; polymer scaffolds; delivery of small molecules; gene delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As Guest Editors, we are pleased to announce the launch of a Special Issue of Pharmaceutics titled “Peptide-Based and Hybrid Carriers for Nucleic Acid Delivery”. Nanoparticles formed by nucleic acids and peptide-based carriers can be a versatile tool for delivery of various genetic constructs (pDNA, siRNA, miRNA, mRNA, etc.) to cells in favor of gene therapy of inherited and acquired diseases. Their advantages include biodegradability and easiness of modification of the structure and amino acid composition. Natural (ligands, various intra- and extracellular signals, etc.) and synthetic (poly)peptide sequences can be used as part of peptide-based and hybrid carriers to overcome the barriers to the transport of therapeutic genetic material into the cells.

We invite you to contribute to the new Special Issue with the aim to gather and feature the latest advances, perspectives, and trends in the development of poly- and oligopeptide and peptide-containing hybrid carriers for the delivery of therapeutic nucleic acids. Both feature articles and literature reviews are acceptable for publication.

Dr. Anton Kiselev
Dr. Korzhikova-Vlakh Evgenia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • nucleic acids
  • gene therapy
  • nucleic acids delivery
  • gene drugs
  • gene delivery
  • (poly)peptide delivery systems
  • peptide-containing hybrid delivery systems
  • design of (poly)peptide carriers
  • (poly)peptide/nucleic acid complexes
  • gene silencing
  • transfection
  • gene expression
  • peptide ligands
  • receptor-mediated delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


18 pages, 3439 KiB  
iRGD-Targeted Peptide Nanoparticles for Anti-Angiogenic RNAi-Based Therapy of Endometriosis
Pharmaceutics 2023, 15(8), 2108; https://doi.org/10.3390/pharmaceutics15082108 - 09 Aug 2023
Viewed by 717
Anti-angiogenic RNAi-based therapy can be considered as a possible strategy for the treatment of endometriosis (EM), which is the most common gynecological disease. Targeted delivery of siRNA therapeutics is a prerequisite for successful treatment without adverse effects. Here we evaluated the RGD1-R6 peptide [...] Read more.
Anti-angiogenic RNAi-based therapy can be considered as a possible strategy for the treatment of endometriosis (EM), which is the most common gynecological disease. Targeted delivery of siRNA therapeutics is a prerequisite for successful treatment without adverse effects. Here we evaluated the RGD1-R6 peptide carrier as a non-viral vehicle for targeted siRNA delivery to endothelial cells in vitro and endometrial implants in vivo. The physicochemical properties of the siRNA complexes, cellular toxicity, and GFP and VEGFA gene silencing efficiency were studied, and anti-angiogenic effects were proved in cellular and animal models. The modification of siRNA complexes with iRGD ligand resulted in a two-fold increase in gene knockdown efficiency and three-fold decrease in endothelial cells’ migration in vitro. Modeling of EM in rats with the autotransplantation of endometrial tissue subcutaneously was carried out. Efficiency of anti-angiogenic EM therapy in vivo by anti-VEGF siRNA/RGD1-R6 complexes was evaluated by the implants’ volume measurement, CD34 immunohistochemical staining, and VEGFA gene expression analysis. We observed a two-fold decrease in endometriotic implants growth and a two-fold decrease in VEGFA gene expression in comparison with saline-treated implants. RNAi-mediated therapeutic effects were comparable with Dienogest treatment efficiency in a rat EM model. Taken together, these findings demonstrate the advantages of RGD1-R6 peptide carrier as a delivery system for RNAi-based therapy of EM. Full article
(This article belongs to the Special Issue Peptide-Based and Hybrid Carriers for Nucleic Acids Delivery)
Show Figures

Figure 1

Back to TopTop